| 0.0213 0.015 (261.02%) | 06-16 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.03 |
1-year : | 0.04 |
| Resists | First : | 0.03 |
Second : | 0.03 |
| Pivot price | 0 |
|||
| Supports | First : | 0.01 |
Second : | 0 |
| MAs | MA(5) : | 0.01 |
MA(20) : | 0 |
| MA(100) : | 0.02  |
MA(250) : | 0.12 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 34 |
D(3) : | 30.4 |
| RSI | RSI(14): 63 |
|||
| 52-week | High : | 0.56 | Low : | 0 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ CARM ] has closed above the upper band by 5.4%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 106.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.03 - 0.03 | 0.03 - 0.03 |
| Low: | 0.01 - 0.01 | 0.01 - 0.01 |
| Close: | 0.02 - 0.02 | 0.02 - 0.02 |
Carisma Therapeutics, Inc. operates as a biopharmaceutical firm dedicated to pioneering chimeric antigen receptor (CAR) macrophage therapies specifically designed to target solid cancerous growths. Its therapeutic approaches are instrumental in modulating both the inherent and acquired functions of the immune system. The company's sophisticated platform draws upon breakthroughs in macrophage science, CAR design, and cell-based treatments to address various human ailments. Notably, Carisma Therapeutics maintains a key strategic alliance with Moderna Inc. Incorporated in 2016 and headquartered in Philadelphia, Pennsylvania, the organization was initially established as CARMA Therapeutics Inc., before rebranding to its current name, Carisma Therapeutics, Inc., in May of 2017.
Fri, 05 Dec 2025
Carisma Therapeutics to delist from Nasdaq, deregister with SEC - Investing.com
Fri, 05 Dec 2025
Carisma Announces Delisting from Nasdaq and SEC Deregistration - PR Newswire
Tue, 14 Oct 2025
CARM Stock Price and Chart — OTC:CARM - TradingView
Fri, 10 Oct 2025
Carisma Therapeutics stock plunges after Nasdaq delisting notice - Investing.com
Mon, 23 Jun 2025
Carisma Therapeutics and OrthoCellix Enter into Definitive - GlobeNewswire
Mon, 31 Mar 2025
Carisma Therapeutics Provides Corporate Updates - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
OTC
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 42 (M) |
| Held by Insiders | 3.014e+007 (%) |
| Held by Institutions | 26.5 (%) |
| Shares Short | 787 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 1.418e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 15.2 % |
| Operating Margin | 96.8 % |
| Return on Assets (ttm) | 33 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 1 % |
| Gross Profit (p.s.) | 296 |
| Sales Per Share | 6.57875e+007 |
| EBITDA (p.s.) | 3.16e+007 |
| Qtrly Earnings Growth | 0.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -22 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.86 |
| Dividend | 0 |
| Forward Dividend | 1.29e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|